Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

Also called NCT01413204

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 272 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01413204
Other papers using this trial's data
  • Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study Expert opinion on pharmacotherapy, 2014-08 DOI, PubMed 25010793

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01413204. Randomized; triple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-08 (actual). Results posted on 2014-06-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TA-7284 Low
Intervention (Drug)
TA-7284 High
Intervention (Drug)
Placebo
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct01413204
Content hash
a4a681a68d972f8049ebdf171da81078cdff3dcd4a3e8da1c0a0e1f03977c151